SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Diemer M)
 

Search: WFRF:(Diemer M) > Factors associated ...

  • Carr, S.B.Imperial College London,Royal Brompton Hospital (author)

Factors associated with clinical progression to severe COVID-19 in people with cystic fibrosis: A global observational study

  • Article/chapterEnglish2022

Publisher, publication year, extent ...

  • Elsevier BV,2022

Numbers

  • LIBRIS-ID:oai:lup.lub.lu.se:a9a8d157-b67b-4a90-987e-0bb4d1e47841
  • https://lup.lub.lu.se/record/a9a8d157-b67b-4a90-987e-0bb4d1e47841URI
  • https://doi.org/10.1016/j.jcf.2022.06.006DOI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:150748769URI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:art swepub-publicationtype
  • Subject category:ref swepub-contenttype

Notes

  • Background: This international study aimed to characterise the impact of acute SARS-CoV-2 infection in people with cystic fibrosis and investigate factors associated with severe outcomes. Methods Data from 22 countries prior to 13th December 2020 and the introduction of vaccines were included. It was de-identified and included patient demographics, clinical characteristics, treatments, outcomes and sequalae following SARS-CoV-2 infection. Multivariable logistic regression was used to investigate factors associated with clinical progression to severe COVID-19, using the primary outcome of hospitalisation with supplemental oxygen. Results: SARS-CoV-2 was reported in 1555 people with CF, 1452 were included in the analysis. One third were aged <18 years, and 9.4% were solid-organ transplant recipients. 74.5% were symptomatic and 22% were admitted to hospital. In the non-transplanted cohort, 39.5% of patients with ppFEV1<40% were hospitalised with oxygen verses 3.2% with ppFEV >70%: a 17-fold increase in odds. Worse outcomes were independently associated with older age, non-white race, underweight body mass index, and CF-related diabetes. Prescription of highly effective CFTR modulator therapies was associated with a significantly reduced odds of being hospitalised with oxygen (AOR 0.43 95%CI 0.31-0.60 p<0.001). Transplanted patients were hospitalised with supplemental oxygen therapy (21.9%) more often than non-transplanted (8.8%) and was independently associated with the primary outcome (Adjusted OR 2.45 95%CI 1.27-4.71 p=0.007). Conclusions: This is the first study to show that there is a protective effect from the use of CFTR modulator therapy and that people with CF from an ethnic minority are at more risk of severe infection with SARS-CoV-2. © 2022

Subject headings and genre

  • MEDICIN OCH HÄLSOVETENSKAP Klinisk medicin Allmänmedicin hsv//swe
  • MEDICAL AND HEALTH SCIENCES Clinical Medicine General Practice hsv//eng
  • Coronavirus
  • COVID-19
  • Cystic fibrosis
  • SARS-CoV-2
  • Transplant
  • cystic fibrosis transmembrane conductance regulator
  • elexacaftor plus ivacaftor plus tezacaftor
  • ivacaftor
  • ivacaftor plus lumacaftor
  • ivacaftor plus tezacaftor
  • oxygen
  • SARS-CoV-2 vaccine
  • adult
  • all cause mortality
  • Article
  • artificial ventilation
  • body mass
  • cohort analysis
  • controlled study
  • coronavirus disease 2019
  • coughing
  • cystic fibrosis
  • demographics
  • disease exacerbation
  • drug efficacy
  • dyspnea
  • extracorporeal oxygenation
  • fatigue
  • female
  • fever
  • forced expiratory volume
  • genotype
  • graft recipient
  • hospital admission
  • hospital patient
  • hospitalization
  • human
  • hypertension
  • intensive care unit
  • intubation
  • invasive ventilation
  • male
  • myalgia
  • obesity
  • observational study
  • outcome assessment
  • oxygen therapy
  • pancreatic insufficiency
  • prescription
  • Pseudomonas aeruginosa
  • Pseudomonas infection
  • race
  • Severe acute respiratory syndrome coronavirus 2
  • underweight
  • complication
  • ethnicity
  • minority group
  • Cystic Fibrosis
  • Cystic Fibrosis Transmembrane Conductance Regulator
  • Ethnicity
  • Humans
  • Minority Groups
  • Oxygen

Added entries (persons, corporate bodies, meetings, titles ...)

  • Stephenson, Anne L.Cystic Fibrosis Canada,Saint Michael's Hospital (author)
  • Diemer, S.Lund University,Lunds universitet,Pediatrik, Lund,Sektion V,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Paediatrics (Lund),Section V,Department of Clinical Sciences, Lund,Faculty of Medicine,Skåne University Hospital(Swepub:lu)st3402di (creator_code:cre_t)
  • Lindberg, U.Lund University,Lunds universitet,Lungmedicin, allergologi och palliativ medicin,Sektion II,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,Respiratory Medicine, Allergology, and Palliative Medicine,Section II,Department of Clinical Sciences, Lund,Faculty of Medicine,Skåne University Hospital(Swepub:lu)med-ukl (creator_code:cre_t)
  • McClenaghan, E (author)
  • Elbert, A (author)
  • Faro, A (author)
  • Abdrakhmanov, O (author)
  • Brownlee, K (author)
  • Burgel, PR (author)
  • Byrnes, CA (author)
  • Cheng, SY (author)
  • Corvol, H (author)
  • Daneau, G (author)
  • Gulmans, V (author)
  • Gutierrez, H (author)
  • Harutyunyan, S (author)
  • Helmick, M (author)
  • Jung, A (author)
  • Kashirskaya, N (author)
  • McKone, E (author)
  • Melo, J (author)
  • Middleton, PG (author)
  • Mondejar-Lopez, P (author)
  • de Monestrol, IKarolinska Institutet (author)
  • Nahrlich, L (author)
  • Pastor-Vivero, MD (author)
  • Rizvi, S (author)
  • Salvatore, M (author)
  • Versmessen, N (author)
  • Zampoli, M (author)
  • Marshall, BC (author)
  • Imperial College LondonRoyal Brompton Hospital (creator_code:org_t)
  • CF Registry Global Collaboration

Related titles

  • In:Journal of Cystic Fibrosis: Elsevier BV21:4, s. E221-E2311569-1993
  • In:Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society: Elsevier BV21:4, s. E221-E2311873-5010

Internet link

Find in a library

To the university's database

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view